Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes

Nephron - Experimental Nephrology

Volumn 103, Issue 3, 2006, Pages

  Flannery, Patrick J ^a   Spurney, Robert F ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Epidermal growth factor receptor; Extracellular signal regulated kinase; Matrix metalloproteases; Podocyte; Transactivation

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CRM 197; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GREEN FLUORESCENT PROTEIN; HEPARIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LOSARTAN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG MECHANISM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PARACRINE SIGNALING; PODOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CELL LINE; COCULTURE TECHNIQUES; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; GREEN FLUORESCENT PROTEINS; HUMANS; IMIDAZOLES; KIDNEY GLOMERULUS; LOSARTAN; METALLOPROTEASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PODOCYTES; PROTEASE INHIBITORS; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TRANS-ACTIVATION (GENETICS);

EID: 33745444308     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092196     Document Type: Article

References (55)

1. Kerjaschki D: Caught flat-footed: podocyte damage and the molecular basis of focal glomerulosclerosis. J Clin Invest 2001;108:1583-1587.
2. Pravenstadt H: Role of the podocyte in glomerular function. Am J Physiol Renal Fluid Electrolyte Physiol 2000;278:F173-F179.
3. Bumpus FM, Catt KJ, Chiu AT, DeGasparo M, Goodfriend T, Husain A, Peach MJ, Taylor DG, Timmermans BMWM: Nomenclature for angiotensin receptors: a report of the nomenclature committee of the council for high blood pressure research. Hypertension 1991;17:720-721.
4. Nouet S, Nahmias C: Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metabol 2000;11:1-6.
5. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carinin DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR, Johnson AL, Timmermans PBMWM: Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989;165:196-203.
6. Sharma M, Sharma R, Greene AS, McCarthy ET, Savin VJ: Documentation of angiotensin II receptors in glomerular epithelial cells. Am J Physiol Renal Fluid Electrolyte Physiol 1998;274:F623-F627.
7. Wang L, Flannery PJ, Spurney RF: Angiotensin II receptor number is upregulated in differentiated podocytes. J Lab Clin Med 2003;142:313-321.
8. Sharma R, Sharma M, Vamos S, Savin VJ, Siegmann TB: Both subtype 1 and 2 receptors of angiotensin II participate in regulation of intracellular calcium in glomerular epithelial cells. J Lab Clin Med 2001;138:40-49.
9. Gloy J, Henger A, Fischer KG, Nitschke R, Bleich M, Mundel P, Schollmeyer P, Greger R, Pavenstadt H: Angiotensin II modulates cellular functions of podocytes. Kidney Int 1998;54(suppl):S168-S170.
10. Henger A, Humber T, Fischer KG, Nitschke R, Mundel P, Schollmeyer P, Greger R, Pavenstadt H: Angiotensin II increases the cytosolic calcium activity in rat podocytes in culture. Kidney Int 1997;52:687-693.
11. Burns GC, Paul SK, Toth LR, Sivak SL: Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997;8:1140-1146.
12. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rhode R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
13. Brenner BM, Cooper ME, Zeeuw DD, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
14. Jafar TH, Schmid CH, Landa, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors reduce the progression of non-diabetic renal disease. Ann Intern Med 2001;135:73-87.
15. Prenzel H, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A: EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999;402:884-888.
16. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, Murasawa S, Mori Y, Kosaki A, Maruyama K, Masaki H, Shibasaki Y, Fujiyama S, Nose A, Iba O, Hasagawa T, Tateishi E, Higashiyama S, Iwasaka T: Angiotensin II signaling and MB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int 2001;60:2153-2163.
17. Thomas WG, Brandenburger Y, Auteliatano DJ, Pham T, Qian H, Hannan R: Adenoviral directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 2002;90:135-142.
18. Touyz RM, Wu XH, He G, Salomon S, Schiffrin EI: Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 2002;39:479-485.
19. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips I: Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor antisense. Circulation 2002;106:909-912.
20. Saito S, Frank GD, Motley ED, Dempsey P, Utsunomiya H, Inagami T, Eguchi S: Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem Biophys Res Commun 2002;294:1023-1029.
21. Eguchi S. Dempsey PJ, Frank GD, Motely ED: Activation of MAPKs by angiotensin II in vascular smooth muscle cells. J Biol Chem 2001;276:7957-7962.
22. Ushio M, Griendling KK, Becker PL, Hilenski L, Halleran S, Alexander RW: Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;21:1594-1600.
23. Schwartz EJ, Cara A, Snoeck H, Ross MD, Sunamoto M, Reiser J, Mundel P, Klotman PE: Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. J Am Soc Nephrol 2001;12:1677-1684.
24. Nelson PJ, Gelman IH, Klotman PE: Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. J Am Soc Nephrol 2001;12:2827-2831.
25. Oppermann M, Freedman NJ, Alexander RW, Lefkowitz RJ: Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C. J Biol Chem 1996;271:13266-13272.
26. DeFea KA, Zalevsky J, Thoma MS. Dery O, Mullins RD, Bunnett NW: D-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 2000;148:1267-1281.
27. Spurney, RF: Role of C-terminal serines in desensitization and phosphorylation of the mouse thromboxane receptor. J Biol Chem 1998;273:28496-28503.
28. Bradford, MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
29. Laemmli, UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
30. Casalini P, Iorio MV, Galmozzi E, Menard S: Role of HER receptors family in development and differentiation. J Cell Physiol 2003;200:343-350.
31. Andrensen BT, Linnoila JJ, Jackson EK, Romero GG: Role of EGFR transactivation in angiotensin II signaling to extracellular regulated kinase in preglomerular smooth muscle cells. Hypertension 2003;41:781-786.
32. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor 1. Nature 1990;346:371-374.
33. Leask A, Abraham DJ: TGF-β signaling and the fibrotic response. FASEB J 2004;18:816-827.
34. vanVliet AI, van Aldersegen IE, Baelde HJ, de Heer E, Bruijn JA: Fibronectin accumulation in glomerulosclerotic lesions: self-assembly sites and the heparin II binding domain. Kidney Int 2002.61:481-489.
35. Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M: High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 2002;290:177-184.
36. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alteration of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707-716.
37. Booz GW, Baker KM: Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996;28:635-640.
38. Briand V, Riva L, Galzin AM: Characterization of the angiotensin II AT1 receptor subtype involved in DNA synthesis in cultured vascular smooth muscle cells. Br J Pharmacol 1994;112:1195-1201.
39. Akishita M, Ito M, Lehtonen JYA, Daviet L, Dzau VJ, Horiuchi M: Expression of the AT2 receptor developmentally programs extracellular signal-regulated kinase activity and influences fetal vascular growth. J Clin Invest 1999103:63-71.
40. Nakajima M, Huchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995;92:10663-10667.
41. Stroth U, Blume A, Mielke K, Unger T: Angiotensin AT2 receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Mol Brain Res 2000;78:175-180.
42. Kobayashi N, Gao SY, Chen J, Saito K, Miyawaki K, Li CY, Pan L, Saito S, Terashita T, Matsuda S: Process formation of the renal glomerular podocyte: is there common molecular machinery for processes of podocytes and neurons? Anat Sci Int 2004;79:1-10.
43. Kobayashi N: Mechanism of the process formation; podocytes versus neurons. Micro Res Tech 2002;57:217-223.
44. Mundel P, Heid HW, Mundel TM, Kruger M, Reiser J, Kriz W: Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J Cell Biol 1997;139:193-204.
45. Putaala H, Soininen R, Kelpelainen P, Wartiovaara J, TryggvasonK: The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 2001;10:1-8.
46. Daniel C, Duffield J, Brunner T, Steinmann-Niggli K, Lods N, Marti HP: Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells. J Pharmacol Exp Ther 2001;297:57-68.
47. Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L: Captopril inhibits the 72 kDa and 97 kDa matrix metalloproteinases. Kidney Int 1993;44:1266-1272.
48. Reinhardt D, Siguschi HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure; Upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002;88:525-530.
49. Lods N, Ferrari P, Frey FJ, Kappeler A, Berthier C, Vogt B Marti HP: Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 2003;14:2861-2872.
50. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Catziantoniou C: Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003;14:1132-1144.
51. Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J: AT1 receptor mutant lacking heterotrimeric G protein coupling activates the src-ras-ERK without nuclear translocation of ERKs. J Biol Chem 2002;277:9268-9277.
52. Frank GD, Motley ED, Sasaki T, Ohba M, Kuroki T, Inagami T, Eguchi S: Requirement of Ca2+ and PKCCCfor Janus kinase 2 activation by angiotensin II: involvement of PYK2. Mol Endocrinol 2002;16:367-377.
53. Liebmann C: Regulation of MAP kinase activity by peptide receptor signaling pathway: paradigms of multiplicity. Cell Signal 2001;13:777-785.
54. Murasawa S, Matsubara H, Mori Y, Masaki H, Tsutsumi Y, Shibasaki Y, Kitabayashi I, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Iba S, Iwasaka: Angiotensin II initiates tyrosine kinase Pyk-2-dependent signaling leading to activation of Rac1-mediated c-Jun NH2-terminal kinase. J Biol Chem 2000;275: 26856-26863.
55. Schmitz U, Thommes K, Beier I, Wagner W, Sachinidis A, Dusing R, Vetter H: Angiotensin II-induced stimulation of p21-activated kinase and c-Jun NH2-terminal kinase is mediated by Rac1 and Nck. J Biol Chem 2001;276:22003-22010.